Discover how we are leading the fight against #infectiousdiseases . Our ground-breaking research and development efforts are aimed at protecting communities worldwide. Learn more 👇

#Vaccination plays a crucial role in adult health and productivity. A recent report from Office of Health Economics highlights the investment case for #adultvaccination , demonstrating its broader societal returns beyond individual health benefits.

Today, Liberia introduces RTS,S into its routine immunisation programme. To support this, our partner Last Mile Health is supporting the training of community health workers on delivering malaria vaccines as part of routine vaccination protocols in Liberia #WorldMalariaDay

Our £1bn investment in global health R&D over 10 yrs will help get ahead of #malaria in lower income countries. From the world’s 1st malaria vaccine to novel antimalarials we support the global elimination of malaria by helping improve prevention and treatment. #WorldMalariaDay

Investing in adult vaccination programmes plays a crucial role in protecting lives, healthcare systems and economies. The new report from Office of Health Economics evidences the Socio-Economic Value of Adult Immunisation Programmes. Check it out 👇

For the past two years, 100% of our Phase III clinical trials have had diversity plans to reflect the people most impacted by a particular disease. Find out more: gsk.to/4aNG1Nk

#News for #Investors and #Media : Our application for a potential expanded indication for our immuno-oncology therapy has been accepted by the U.S. FDA with Priority Review status. Learn more here: gsk.to/3xPNPzv

Today Save the Children UK is launching a new 'Immunisation Accelerator' to find innovations that address the barriers that exist for children receiving vaccinations. Here's Save the Children’s Dr Tewodros Gebremichael to explain more 👇 gsk.to/44abLtu

Margaret’s family has been deeply affected #malaria , but thanks to the support of Gaudenciah, a community health promoter trained by Amref Health Africa through our partnership, she is now able to access the healthcare she needs. #WorldMalariaDay gsk.to/3xJRKOj

#News for #investors and #media : Today we have announced phase III data in uncomplicated urogenital gonorrhoea (GC).
Find out more gsk.to/4aAlU5a

For #investors and #media : Today we announced new positive long-term follow-up trial data in shingles.
Find out more: gsk.to/4aXTRvY

#News for #Media and #Investors : Today, we announced that the Biologics License Application for our vaccine candidate has been accepted by the U.S. FDA.

Find out more: gsk.to/49FPPrl

Closing the health equity gap is better for everyone, not just those who face barriers to accessing high quality healthcare.

This is how companies like GSK are working with partners to find solutions:
gsk.to/43RijNj

All patients deserve access to high quality healthcare, yet the needs of many go unmet due to preventable factors.

This is why closing the health equity gap not only benefits those facing barriers to access, but society as a whole: gsk.to/43ZlvGP

“A disease that was once almost uniformly fatal is now a disease that can be controlled with treatment” – getting ahead of HIV is one way we’re innovating to help prevent and change the course of disease.

Find out more 👇

ViiV Healthcare gsk.to/3xk3iHH

So far, 75 health systems around the world have committed to lowering their carbon footprint.

Read the latest FT article, in partnership with GSK, to discover how low carbon inhalers could be key to reducing their emissions. gsk.to/3TMhRLR

Biomarker testing is helping doctors find precision treatments for patients that could dramatically improve health outcomes for everything from cancer to respiratory disease: gsk.to/4ap5cFu

Meet Lou – a patient with #multiplemyeloma who shares what life can be like for those living with this blood cancer. This #MyelomaActionMonth we are inspired to keep driving progress for patients like Lou. Get to know her story here: gsk.to/3xcUjbf

Modern medicine has revolutionised the way we live, but the challenges to our health are evolving. We believe prevention is the best medicine – for patients, societies and our economy.

This is why: gsk.to/43JFUj1

Our Mapping myelofibrosis podcast allows us to sit down with myelofibrosis experts, to learn more and discuss how we can collectively work together to close the gaps in complex #bloodcancers .
Watch it here: gsk.to/4am8xoM
#MappingMF